# MycoMedica Life Sciences, PBC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mycomedica-life-sciences-pbc

- Industry: Pharmaceuticals
- Headquarters: Shelton, US
- Website: www.mycomedica.bio
- Total disclosed funding: $68M
- Latest round: Series A (Jun 1, 2022)
- Investors on record: 3

## About

MycoMedica Life Sciences is a biotechnology company focused on developing innovative mycological solutions for health and wellness. The company specializes in harnessing the medicinal properties of mushrooms to enhance therapeutic outcomes.MycoMedica Life Sciences, PBC, founded in 2021 and headquartered in Shelton, US, is dedicated to advancing mycological health solutions. The company has undergone strategic pivots to focus on pre-clinical research and FDA approval processes. Founder Pamela Kryskow has a history of entrepreneurship, bringing expertise from previous ventures. As of June 1, 2022, the company raised USD 60.00 mn in Series A funding led by KittyHawk Ventures, Obvious Ventures, and True Ventures, bringing the total amount raised to USD 60.00 mn with a current valuation of USD 295.54 mn.MycoMedica Life Sciences offers a range of innovative health solutions utilizing the therapeutic properties of mushrooms. Key areas of focus include developing mycological products aimed at improving health outcomes through natural remedies. The company serves a diverse clientele, addressing various health needs, and is positioned to cater to markets across North America, Europe, and Asia-Pacific with tailored solutions.The company generates revenue primarily through subscription-based models and long-term contracts. Clients pay monthly or annual fees for access to MycoMedica's health solutions. The pricing structure includes various tiers based on features and performance, ensuring customers receive comprehensive support. The transaction model fosters strong partnerships with clients, reinforcing MycoMedica's reliable revenue stream anchored in recurring subscriptions.MycoMedica Life Sciences aims to advance its pre-clinical research and begin initial clinical trials for the Stamets Stack, targeting FDA approval for an Investigational New Drug Application (IND). The recent funding round of USD 60.00 mn will be utilized to support these initiatives, which are essential to the company’s growth strategy. Additionally, efforts are underway to expand into new geographic markets, with specific plans to enter additional regions by 2024.

## Funding rounds

- Series A, Jun 1, 2022, $60M — True Ventures, Obvious, KittyHawk Ventures
- Seed, Jul 1, 2021, $8M — Obvious, KittyHawk Ventures

## Investors

- Obvious (https://capitalatlas.ai/funds/obvious) — Seed, Series A
- KittyHawk Ventures (https://capitalatlas.ai/funds/kittyhawk-ventures) — Seed, Series A
- True Ventures (https://capitalatlas.ai/funds/true-ventures) — Series A